David Sinclair

David Sinclair is a Professor of Genetics at Harvard Medical School and an expert in aging biology, known for his research into understanding the aging process and methods to slow its effects. After groundbreaking postdoctoral research at M.I.T. with Dr. Leonard Guarente, where he contributed to the co-discovery of a cause of aging in yeast and the role of Sir2 in epigenetic changes, David Sinclair joined Harvard Medical School in 1999.

His work in 2008 introduced the RCM Hypothesis of Aging, linking DNA breaks and epigenetic factor relocalization to aging, followed by The Mitochondrial Oasis Hypothesis in 2009, addressing age-related physiological decline due to mitochondrial-nuclear miscommunication. Demonstrating his commitment to translating scientific discovery into therapeutic applications, Sinclair co-founded Sirtris Pharmaceuticals in 2004, a company focused on sirtuin activators that was later acquired by GlaxoSmithKline. Further expanding his entrepreneurial footprint in biotechnology, Sinclair co-founded Genocea Biosciences in 2006, OvaScience in 2011, and CohBar in 2011. He continued this trajectory with the establishment of Metro Biotech in 2015 and Animal Bioscience in 2017, all aimed at leveraging his research for therapeutic innovations.

Through his extensive body of work, David Sinclair remains a leading authority in the field of aging biology, continuously pushing the boundaries of scientific understanding and its practical application to human health.